Skip to main content
0

Pharmaceutical company Novartis is planning a phase 2 clinical trial of NIO752, an investigational drug designed to reduce the production of tau protein. The aim is to evaluate whether the drug is safe, tolerable and what it does in the bodies of people with primary tauopathies like Progressive Supranuclear Palsy and Corticobasal Syndrome. The trial will be a ‘Basket Trial’ where one drug will be trialled in people living with different conditions at the same time.

Who will the phase 2 trial include?

Novartis plans to enrol around 48 people, with 16 in each cohort, with primary tauopathies as follows:

  • People with PSP subtypes other than Richardson’s syndrome.
  • People with Corticobasal Syndrome (CBS) unrelated to Alzheimer’s disease.
  • People with Frontotemporal Dementia caused by a MAPT gene mutation.

What is NIO752?

The drug NIO752 is an antisense oligonucleotide. It works by binding to the instructions in our brain that make the tau protein and disrupting this process, therefore reducing the amount of tau protein that is produced. It is the same drug currently being used in the phase 3 PRESERVE-PSP trial, which is recruiting 300 people across the globe with PSP Richardson’s syndrome.

How are these clinical trials conducted?

Both clinical trials are randomised, double-blind and placebo-controlled. This means that participants are randomly allocated either the study drug or the placebo (a drug which looks the same but has no effect). The trial being double-blind means that neither the participant nor the researcher will know what the participant is taking. Both trials also include an open-label extension, where everyone is offered the trial drug after the trial has completed if data suggest there is a benefit.

Where can you find out more about this PSP & CBS clinical trial?

The phase 2 trial is listed as “not yet recruiting.” If you’re interested in taking part or sharing the details with someone you support, you can find the eligibility criteria and check for recruitment updates in the study record here.

Interested in PSP & CBD research?

Complete our Expression of Interest in Research form for engagement and participation in research studies.

Leave a Reply